Marksans Pharma Limited (IN:MARKSANS)
:MARKSANS
Want to see IN:MARKSANS full AI Analyst Report?
MARKSANS Stock Chart & Stats
₹182.05
-₹6.40(-2.21%)
At close: 4:00 PM EST
₹182.05
-₹6.40(-2.21%)
Day’s Range― - ―
52-Week Range₹155.50 - ₹270.60
Previous CloseN/A
Volume681.00K
Average Volume (3M)99.03K
Market Cap
₹86.21B
Enterprise Value₹85.57B
Total Cash (Recent Filing)₹6.71B
Total Debt (Recent Filing)₹3.32B
Price to Earnings (P/E)18.0
Beta1.47
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)2.50
Shares Outstanding453,163,760
10 Day Avg. Volume119,310
30 Day Avg. Volume99,030
Financial Highlights & Ratios
PEG Ratio1.24
Price to Book (P/B)4.08
Price to Sales (P/S)3.83
P/FCF Ratio298.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.6
Revenue Forecast (FY)₹33.60B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And MarginsMarksans' ~20.45% revenue growth coupled with a 56.38% gross margin and 14.51% net margin indicate durable demand and effective cost control across its product mix. Sustained high margins support reinvestment in manufacturing, regulatory filings and commercial expansion, bolstering earnings resilience over the medium term.
Conservative Balance Sheet, Low LeverageA 76.14% equity ratio and 0.13 debt-to-equity show low financial leverage and reduce interest and refinancing risk. This balance-sheet strength provides flexibility to fund capex, regulatory approvals or strategic acquisitions without materially increasing financial stress, supporting stable operations across cycles.
High Operating Profitability And ReturnsRobust operating margins (EBIT 43.04%, EBITDA 20.15%) and a ~15.4% ROE reflect operational efficiency and effective use of capital in manufacturing generics/OTC. These durable margins underpin cash generation potential and give the company room to defend market share and invest in higher-value product launches.
Bears Say
Weak Operating Cash Flow ConversionOperating cash flow declined 10.28% and OCF converts only ~54% of reported net income, indicating weaker cash realization from operations. If persistent, this constrains self-funding of working capital and regulatory filings, potentially forcing more external financing or slower product rollouts over time.
EPS Growth Lagging Revenue GrowthEPS declined modestly (~-2.17%) despite double-digit revenue growth, suggesting dilution, one-off charges, or adverse mix effects that limit shareholder earnings growth. Continued EPS underperformance versus sales could reduce returns to investors and limit retained earnings available for strategic initiatives.
Exposure To Generic Pricing And Approval RisksMarksans' reliance on generic formulations and regulated-market launches makes revenue growth contingent on approvals and vulnerable to competitive pricing. These structural factors can produce lumpy, approval-dependent revenue and sustained pricing pressure that may compress margins and slow durable profit expansion.
Marksans Pharma Limited News
MARKSANS FAQ
What was Marksans Pharma Limited’s price range in the past 12 months?
Marksans Pharma Limited lowest stock price was ₹155.50 and its highest was ₹270.60 in the past 12 months.
What is Marksans Pharma Limited’s market cap?
Marksans Pharma Limited’s market cap is ₹86.21B.
When is Marksans Pharma Limited’s upcoming earnings report date?
Marksans Pharma Limited’s upcoming earnings report date is Jun 01, 2026 which is in 34 days.
How were Marksans Pharma Limited’s earnings last quarter?
Marksans Pharma Limited released its earnings results on Feb 05, 2026. The company reported ₹2.5 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.5.
Is Marksans Pharma Limited overvalued?
According to Wall Street analysts Marksans Pharma Limited’s price is currently Overvalued.
Does Marksans Pharma Limited pay dividends?
Marksans Pharma Limited pays a Annually dividend of ₹0.8 which represents an annual dividend yield of 0.44%. See more information on Marksans Pharma Limited dividends here
What is Marksans Pharma Limited’s EPS estimate?
Marksans Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marksans Pharma Limited have?
Marksans Pharma Limited has 453,163,760 shares outstanding.
What happened to Marksans Pharma Limited’s price movement after its last earnings report?
Marksans Pharma Limited reported an EPS of ₹2.5 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.555%.
Which hedge fund is a major shareholder of Marksans Pharma Limited?
Currently, no hedge funds are holding shares in IN:MARKSANS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
Laurus Labs Ltd.
―